Genetic analysis of 53 paediatric glioblastoma tumours has indicated that around 10% of glioblastomas carry novel gene fusions involving the proto-oncogene MET. These fusions impaired cell cycle regulation, and induced aggressive glioblastomas in mice. MET inhibitors have been approved for treatment of certain non-CNS cancers, and MET inhibition improved survival in xenograft models of glioblastoma featuring MET fusions. In the clinical setting, however, combination treatments are likely to be needed to avoid tumour resistance.
References
Bender, S. et al. Recurrent MET fusion genes represent a drug target in pediatric glioblastoma. Nat. Med. http://dx.doi.org/10.1038/nm.4204 (2016)
Rights and permissions
About this article
Cite this article
Malkki, H. MET fusion genes implicated as treatment target in paediatric glioblastoma. Nat Rev Neurol 12, 679 (2016). https://doi.org/10.1038/nrneurol.2016.174
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrneurol.2016.174
